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Abstract 
Further optimization of the trimethoxyphenyl scaffold of parent chalcone compound 
(2a) by introducing a pyridine ring afforded a series of novel pyridine-chalcone 
derivatives as potential anti-tubulin agents. All the target compounds were evaluated 
for their antiproliferative activities. Among them, representative compound 16f 
exhibited the most potent activity with the IC50 values ranging from 0.023 to 0.045 μM 
against a panel of cancer cell lines. Further mechanism study results demonstrated that 
compound 16f effectively inhibited the microtubule polymerization by binding to the 
colchicine site of tubulin. Moreover, cellular mechanism studies disclosed that 16f 
caused G2/M phase arrest, induced cell apoptosis and disrupted the intracellular 
microtubule network. Also, 16f reduced the cell migration and disrupted the capillary-
like tube formation of human umbilical vein endothelial cells (HUVECs). Importantly, 
16f significantly inhibited tumor growth in H22 xenograft models without apparent 
toxicity, which was stronger than the reference compound CA-4, indicating that it is 
worthy to investigate 16f as a potent microtubule-destabilizing agent for cancer therapy. 
Keywords: pyridine; chalcone; microtubule-destabilizing agent; colchicine site; anti-
vascular; antitumor  
 
1. Introduction 
Microtubules as the key components of the cytoskeleton, are long, filamentous, tube-
shaped protein polymers which are essential in all eukaryotic cells [1]. Microtubules, 
which are composed of α-tubulin and β-tubulin heterodimers, play vital roles in cell 
proliferation, trafficking, signaling, migration, cell division and mitosis [2]. For this 
reason, microtubules become an important target for anticancer drugs. Microtubule-
active drugs generally bind to one of three main classes of sites on tubulin, the paclitaxel 
site, the vinca domain and the colchicine domain [3]. Those inhibitors that bind to the 
taxane or vinca alkaloid binding sites have many disadvantages such as extremely 
structural complexity, low aqueous solubility, multidrug resistance and dose-limiting 
toxicity [4]. Hence, colchicine binding site inhibitors (CBSIs) are undergoing intensive 
investigation in recent decades [5]. 
Combretastatin A-4 (1, CA-4), an excellent colchicine binding site inhibitor which 
was isolated from the bark of the African willow tree Combretum caffrum, displayed 
potent antimitotic and vascular disrupting profiles [6]. Other typical colchicine binding 
site inhibitors were chalcone compounds 2a and 2b which were discovered by Ducki 
et al. in 1998, both showing remarkable antiproliferative activities [7]. The 3,4,5-
trimethoxyphenyl (TMP) moiety of CA-4 was vital for its activity since the 4-methoyl 
group formed a critical hydrogen bond with the residue Cys241 [8-10]. Attempts to 
modify the TMP moiety usually led to reduced anticancer potency [11-14]. However, 
in 2017, Yin et al. introduced a selenium atom to replace the oxygen atom at the C-3 
position of TMP to afford compound 3a, which showed improved activities both in 
vitro and in vivo compared to its parent compound isocombretastatin A-4 (IsoCA-4) 
[15]. Recently, Li et al. discovered a unique 3-methoxybenzo[4,5]-dioxene moiety 3b 
which exhibited improved antiproliferative activity compared with the compound 
bearing TMP moiety [16]. Other efforts have also been made to discover new moieties 
to replace the TMP moiety. In 2015, Alami and colleagues reported the discovery of 
compound 3c which bears a quinazoline nucleus [17], and it displayed nanomolar-level 
cytotoxicity against various human cancer cell. In 2017, Alami’s group reported an 
isoCA-4 analog 3d with a quinoline moiety [18]. In 2018, Millier et al. first reported 
the high-resolution X-ray crystal structure of the heterocyclic-fused pyrimidine 
compound 3e complexed with tubulin, and the results showed that the N-1 atom formed 
hydrogen bond with the residue Cys241, demonstrating that quinoline or quinazoline 
moieties that have N-1 atom might be the suitable surrogates of the traditional TMP 
moiety for binding to the colchicine site [19]. Meanwhile, our group also discovered a 
quinoline-chalcone compound 3f by replacing TMP with quinoline moiety, and its 
antiproliferative activity was improved for 8-10 folds as well as the improvement of the 
solubility [20]. 
Nitrogenous heterocycles, such as pyridine, quinoline, pyrimidine and piperidine, are 
privileged building blocks in drugs [21]. Pyridine plays important roles in drug 
development, which can be found in a vast number of drugs like imatinib [22], 
telithromycin [23], indinavir [24] and acalabrutinib [25]. Even though the number of 
CA-4 analogs has been more than 28000 [26], compounds containing pyridine ring 
replacing of TMP have rarely been reported.  
Recently, our group has focused on discovering and developing novel anticancer 
agents targeting tubulin-microtubule system, such as chalcone analogs bearing vinyl 
sulfone skeleton [27], 4-arylisochromenes [28], quinazolines that occupy three zones 
of colchicine domain [29] and quinoline-indole derivatives [30]. Inspired by Millier’s 
work [19], we assumed that the N-1 atom of pyridine might also form a hydrogen bond 
with Cys241 in the colchicine, thus pyridine might be introduced into the structures of 
CBSIs as an alternative ring of TMP moiety.  
In this work, we continued our efforts in the modification works of the parent 
compound 2a by replacing the TMP moiety with a pyridine ring. Thus, a series of novel 
pyridine-chalcone derivatives were designed and synthesized (Figure 2). Herein, we 
would like to report the synthesis and evaluation of their antitumor activities in vitro 
and in vivo. 
 
 
Figure 1. A) Structures of the representative colchicine binding site inhibitors (CBSIs); B) CBSIs 
reported to modify TMP; C) CBSIs containing nitrogenous heterocycles in replace of TMP. 
 
Figure 2. Design strategy of novel pyridine-chalcone derivatives. 
 
2. Results and discussion 
2.1 Chemistry 
The synthetic route for the synthesis of pyridine-chalcone derivatives 15a-f and 16a-
f is outlined in Scheme 1. The intermediates 9a, 9b and 14 are synthesized by two 
different routes. The starting material 2,6-dichloroisonicotinic acid (4) underwent 
nucleophilic attack by ethylmagnesium bromide (EtMgBr) to give intermediate 5 which 
was then treated with 2-bromoethanol to give intermediate 6. Intermediates 7 and 8 
were prepared by treating intermediate 6 with sodium methoxide in 60 ℃ and 100 ℃, 
respectively, followed by deprotection with hydrochloric acid to afford intermediates 
9a and 9b, respectively. As for intermediate 14, the starting material 2,6-
dichloroisonicotinic acid (4) was first treated with N-methoxymethanamine to obtain 
intermediate 10 then underwent nucleophilic attack by methylmagnesium bromide 
(MeMgBr) to give intermediate 11. Then the procedures are the same as 9a and 9b. 
Subsequently, ketone 9a, 9b and 14 were underwent Aldol reaction with a variety of 
aldehydes to obtain target compounds 15a-r and 16a-f. 
Scheme 1. The synthetic route for the preparation of compounds 15a-f and 16a-f a.  
 a Reagents and conditions: (a) EtMgBr, HCOOEt, THF, N2, rt, 1 h; (b) BrCH2CH2OH, DBU, Tol, 
80 ℃, overnight; (c) MeONa, MeOH, 60 ℃, overnight; (d) MeONa, MeOH, 100 ℃, overnight; (e) 
1M HCl, MeOH, 60 ℃, 1 h; (f) EDCI, HOBt, N-methoxymethanamine, Et3N, DCM, rt, 8 h; (g) 
CH3MgBr, THF, N2, rt, 1 h; (h) NaOH, EtOH, rt, 3 h. 
Pyridine-indole derivatives 18a-i with different substituted positions on the indole 
ring were synthesized as shown in Scheme 2. Indolealdehyde derivatives were prepared 
by Vilsmeier-Haack reaction with DMF and phosphoryl chloride. Target compounds 
18a-i were synthesized through Aldol reactions by treating indolealdehyde with ketone 
9 in the presence of piperidine. 
 
Scheme 2. The synthetic route for the preparation of compounds 18a-i a.  
 
a Reagents and conditions: (a) POCl3, DMF, 0 ℃, 10 min; (b) piperidine, EtOH, reflux, overnight. 
 
Compounds 19a-g were prepared as shown in Scheme 3. The compounds 18a and 
18h was treated with methyl iodine and ethyl iodine to give the target compounds 19a, 
19b and 19h, respectively. And compound 18a was converted to 19c using 
formaldehyde with sodium hydroxide under refluxing condition. Also, compound 18a 
was reacted with acetyl chloride, 2-furoyl chloride and benzoyl chloride to provide the 
corresponding compounds 19d-f. 
Scheme 3. The synthetic route for the preparation of compounds 18a-g a. 
 
a Reagents and conditions: (a) NaH, MeI, DMF, 0 ℃, 1 h; (b) HCHO, EtOH, NaOH, reflux, 1 h; (c) 
acyl chloride, NaOH, DCM, rt, 2 h.  
2.2 In vitro antiproliferative activity 
Target compounds 15a-f, 16a-f, 18a-i and 19a-g were evaluated for their in vitro 
antiproliferative efficacy against K562 cells by the MTT assays with CA-4 as the 
reference. As shown in Table 1, compounds with indole moieties as ring B showed 
favorable activity except 18b, 18f, 18h and 19b. Compound 16f that bear 3-hydroxy-
4-methoylphenyl moiety displayed the most potent activity with the IC50 value of 0.023 
μM, which was about 3-fold increase in activity when compared with the parent 
compound 2a (IC50 = 0.068 μM), and was slightly less potent than the CA-4 (IC50 = 
0.011 μM). The methyl substituted at the α-position of unsaturated carbonyl group was 
favorable for the improvement of activity (15a vs 16a, 15b vs 16b, 15c vs 16c and 15e 
vs 16f), which was accordance with the results in the previous reports [7]. Besides, the 
exposed hydroxyl on ring B was essential for maintaining the activity (16b vs 16f). 
Moreover, the substituents on the pyridine were also critical to the activity (16d, 16e 
and 16f), indicating that the electron-donating groups (EDG) were more favorable than 
the electron-withdraw groups (EWG). We proposed that the EDG increased the electron 
density of the N-1 of pyridine, which was beneficial to form a hydrogen bond with the 
critical residue Cys241. Also, the results indicated that the 3-substitued indoles were 
more favorable (18a vs 18h and 18i), and while substituents at N-1 of indole ring were 
unfavorable to activity (18a vs 18b-g, 18a vs 19a-f ). 
Table 1. Antiproliferative activities of compounds 15a-f, 16a-f, 18a-g and 19a-g against K562 cell 
line a. 
 
Compd. 
IC50 values (μM)b 
Compd. 
IC50 values (μM)b 
K562 K562 
15a > 1 18d 0.352 ± 0.004 
15b > 1 18e 0.191 ± 0.008 
15c > 1 18f > 1 
15d > 1 18g 0.106 ± 0.006 
15e 0.983 ± 0.013 18h > 1 
15f > 1 18i 0.142 ± 0.036 
16a 0.554 ± 0.017 19a 0.700 ± 0.023 
16b > 1 19b > 1 
16c > 1 19c 0.058 ± 0.006 
16d 0.156 ± 0.012 19d 0.086 ± 0.008 
16e 0.138 ± 0.011 19e 0.060 ± 0.003 
16f 0.023 ± 0.002 19f 0.070 ± 0.003 
18a 0.051 ± 0.003 19g 0.952 ± 0.017 
18b > 1 2a 0.068± 0.002 
18c 0.983 ± 0.018 CA-4 0.011 ± 0.001 
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments. 
 
Table 2. Antiproliferative activities of representative compounds against five cancer cell lines and 
one normal cell line a 
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
MTT assay as described in the Experimental Section. 
b IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments. 
 
In consideration of the prominent antiproliferative activities of the newly pyridine-
chalcone derivatives against K562 cells, we tend to further evaluate the biological 
functions against more cancer cell lines. Human hepatocellular carcinoma (HepG2), 
epidermoid carcinoma of the nasopharynx (KB), human ileocecal cancer cells (HCT-8) 
human breast cancer cells (MDA-MB-231), and hepatoma 22 cells (H22) were selected 
for the further evaluation of activity. In addition, one normal non-cancerous cell line - 
human normal liver cells (L-O2) - was chosen to evaluate the toxicity of these 
compounds. The cytotoxic data of representative compounds against these four cancer 
Compd. 
IC50 values (μM)b 
HepG2 KB HCT-8 
MDA-MB-
231 
 
H22 
 
L-O2 
15e 0.991 ± 0.021 1.018 ± 0.015 0.997 ± 0.010 1.128 ± 0.011 0.928 ± 0.065 4.226 ± 0.321 
16d 0.183 ± 0.008 0.162 ± 0.003 0.177 ± 0.005 0.195 ± 0.009 0.177 ± 0.011 0.399 ± 0.031 
16e 0.132 ± 0.010 0.147 ± 0.012 0.139 ± 0.012 0.162 ± 0.013 0.142 ± 0.014 0.768 ± 0.054 
16f 0.047 ± 0.002 0.045 ± 0.001 0.047 ± 0.003 0.041 ± 0.004 0.043 ± 0.002 0.157 ± 0.013 
18a 0.085 ± 0.005 0.090 ± 0.003 0.095 ± 0.003 0.079 ± 0.002 0.088 ± 0.012 0.408 ± 0.036 
18d 0.392 ± 0.009 0.324 ± 0.013 0.335 ± 0.011 0.320 ± 0.016 0.336 ± 0.025 1.271 ± 0.121 
18e 0.364 ± 0.012 0.421 ± 0.022 0.379 ± 0.018 0.364 ± 0.015 0.428 ± 0.041 1.102 ± 0.104 
18g 0.124 ± 0.012 0.137 ± 0.013 0.127 ± 0.010 0.153 ± 0.014 0.127 ± 0.013 0.628 ± 0.057 
18i 0.157 ± 0.003 0.143 ± 0.008 0.152 ± 0.006 0.148 ± 0.005 0.138 ± 0.008 0.728 ± 0.069 
19c 0.092 ± 0.003 0.109 ± 0.006 0.121 ± 0.009 0.088 ± 0.007 0.098 ± 0.007 0.417± 0.032 
19e 0.068 ± 0.002 0.072 ± 0.006 0.091 ± 0.008 0.082 ± 0.008 0.075 ± 0.002 0.338 ± 0.031 
19f 0.093 ± 0.001 0.107 ± 0.001 0.110 ± 0.003 0.093 ± 0.007 0.108 ± 0.011 0.528 ± 0.042 
2a 0.102± 0.010 0.108 ± 0.005 0.104 ± 0.010 0.102 ± 0.009 0.132 ± 0.008 0.421 ± 0.037 
CA-4 0.012± 0.001 0.011 ± 0.002 0.010 ± 0.001 0.010 ± 0.001 0.008 ± 0.001 0.095 ± 0.011 
cell lines were shown in Table 2, which showed that all these chosen compounds 
displayed potent activities against these four cancer cell lines. Moreover, the structure 
activity relationships (SARs) were similar to their performances in K562 assays. Also, 
the K562 cell was the most sensitive cell line among five cancer cell lines tested, and 
the most active compound 16f exhibited remarkable activity with IC50 values ranging 
from 0.023 to 0.047 μM, which was about 3-fold improvement of activity when 
compared with the parent compound 2a. The SARs of synthesized compounds were 
summarized in Figure 3. 
 
 
 
Figure 3. Summarized SARs of synthesized compounds. 
 
2.3 In vitro tubulin polymerization inhibitory assay 
 To verify whether the target molecules interacted with microtubule systems, 16f, 
the most cytotoxic compounds, was selected for the experiment of effects on 
microtubule dynamics. Also colchicine（a typical microtubule-destabilizing agent） 
and taxol (microtubule-stabilizing agent) were chosen as the controls. As shown in 
Figure 4, the fluorescence emission of 16f was less than the control group and similar 
to the colchicine group, indicating that 16f was a microtubule-destabilizing agent. 
Moreover, the calculated IC50 value of 16f in inhibiting tubulin polymerization was 
2.08 μM, which was better than the CA-4 (IC50 = 2.17 μM) and the parent compound 
2a (IC50 =3.05 μM) (Table 3). In addition, the test of competing with [3H]-colchicine 
in binding to tubulin was performed, indicating that 16f bound to the colchicine binding 
site with the potency about 87.9% at 5 μM, (Table 3). Hence, 16f was chosen for further 
mechanism studies due to its excellent activities both in the in vitro antiproliferative 
assay and tubulin polymerization inhibition assay. 
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Figure 4. Effects of 16f on tubulin polymerization in vitro. Purified tubulin protein at 2 mg/mL in 
a reaction buffer was incubated at 37 °C in the presence of 1% DMSO, test compounds (16f at 5 or 
10 μM), Colchicine (10 μM) or Taxol (10 μM). Polymerizations were followed by an increase in 
fluorescence emission at 350 nm over a 60 min period at 37 °C. The experiments were performed 
three times. 
 
Table 3. Inhibition of tubulin polymerizationa and colchicine binding to tubulinb 
Compd. 
inhibition of tubulin polymerization 
inhibition of colchicine binding 
(%) inhibition ± SD 
IC50 (μM) 1 μM 5 μM 
16f 2.08 ± 0.12 75.1 ± 1.63   87.9 ± 2.18 
CA-4 2.17 ± 0.14 81.2 ± 2.01   91.7 ± 4.40 
2a 3.05 ± 0.15 70.2 ± 1.71   78.3 ± 3.39 
a The tubulin assembly assay measured the extent of assembly of 2 mg/mL tubulin after 60 min at 
37 °C. Data are presented as mean from three independent experiments.  
b Tubulin, 1 μM; [3H]-colchicine, 5 μM; and inhibitors, 1 or 5 μM. 
 
2.4. Anti-microtubule effects in K562 cells 
Immunofluorescent assay was performed to investigate the effects of compound 
16f on microtubule networks. As shown in Figure 5, K562 cells and MAD-MB-231 
cells without drug treatment exhibited normal filamentous arrays. However, after 
exposure to 16f (10 nM, 20 nM, 40 nM to K562, and 20 nM, 40 nM, 80 nM to MAD-
MB-231) for 24 h, the microtubule networks in cytosol were disrupted; these results 
indicated that 16f can induce a dose-dependent collapse of the microtubule networks.   
 
Figure 5. A) Effects of 16f on the cellular microtubule network visualized by immunofluorescence. 
K562 cells were treated with vehicle control 0.1% DMSO, 16f (10 nM), 16f (20 nM), and 16f (40 
nM). B) Effects of 16f on the cellular microtubule network visualized by immunofluorescence. 
MAD-MB-231 cells were treated with vehicle control 0.1% DMSO, 16f (20 nM), 16f (40 nM), and 
16f (80 nM).Then, the cells were fixed and stained with anti-α-tubulin-FITC antibody (green), Alexa 
Fluor 488 dye and counterstained with DAPI (blue). The detection of the fixed and stained cells was 
performed with an LSM 570 laser confocal microscope (Carl Zeiss, Germany). 
 
2.5 Cell cycle analysis 
Since most microtubule polymerization inhibitors disrupt cell mitosis and exert cell 
cycle arrest effects, the effect of 16f on cell cycle progression using propidiumiodide 
(PI) staining in K562 cells was examined. As illustrated in Figure 6A and 6B, 
incubation with 16f blocked the cell cycle at the G2/M phase. Compared to the control 
cells incubated with DMSO, the incubation of K562 cells with increasing 
concentrations of 16f (15, 30, and 60 nM) increased the percentage of cells in the G2/M 
phase from 7.10% to 33.22%.  
 
 
Figure 6．A) Compound 16f induced G2/M arrest in K562 cells. K562 cells were incubated with 
varying concentrations of 16f (0, 15, 30, and 60 nM) for 48 h. Cells were harvested and stained with 
PI and then analyzed by flow cytometry. The percentages of cells in different phases of the cell 
cycle were analyzed by ModFit 4.1; B) Histograms display the percentage of cell cycle distribution 
after treatment with 16f. 
 
2.6 Cell apoptosis analysis 
Most microtubule polymerization inhibitors can induce cell apoptosis by up-
regulating the expression of pro-apoptotic proteins and down-regulating the expression 
of antiapoptotic proteins. Aiming to assess whether compound 16f would induce cell 
apoptosis, an annexin VFITC and propidium iodide (PI) assay was carried out. As 
shown in Figure 7A and 7B, the percentage of apoptotic cells after the 48 h treatment 
was only 3.42% in the control group, but the total numbers of early (annexin-V+/PI−) 
and late (annexin-V+/PI+) apoptotic cells increased to 15.79%, 39.01% and 56.07% 
after treatment with 16f at 10, 20, and 40 nM for 48 h, respectively. These results 
confirmed that compound 16f effectively induced cell apoptosis in K562 cells in a dose-
dependent manner. 
 Figure 7. A) Compound 16f induced apoptosis in K562 cells. K562 cells were incubated with 
varying concentrations of 16f (0, 10, 20, and 40 nM). After 48 h of incubation, cells were collected 
and stained with Annexin V/PI, followed by flow cytometric analysis. The percentages of cells in 
each stage of cell apoptosis were quantified by flow cytometry: (upper left quadrant) necrosis cells; 
(upper right quadrant) late-apoptotic cells; (bottom left quadrant) live cells; and (bottom right 
quadrant) early apoptotic cells. B) Histograms display the percentage of cell distribution after 
treatment with 16f. 
 
2.7 Mitochondrial membrane potential analysis. 
Decreased mitochondrial membrane potential (MMP) has been implicated as an early 
event in apoptotic cells. Thus, the effect of compound 16f on MMP of K562 cells was 
determined by staining with lipophilic cationic JC-1 dye. When treated with 16f at 
concentrations of 0, 10, 20 and 40 nM for 24 h, the number of K562 cells with collapsed 
MMP increased to 5.75%, 16.44%, 28.10% and 44.49%, respectively. (Figure 8), 
suggesting that 16f caused mitochondrial depolarization of K562 cells in the process of 
apoptosis. 
 
 Figure 8. Effects of 16f on the mitochondrial membrane potential of K562 cells. A) Incubation with 
different concentrations (0, 10, 20, and 40 nM) of 16f in K562 cells for 24 h prior to staining with 
JC-1 dye, the number of cells with collapsed mitochondrial membrane potentials was determined 
by flow cytometry analysis. B) Histograms display the percentage of green fluorescence. 
 
2.8 In vitro evaluation of anti-vascular activity 
In view of such facts that most CBSIs possess vascular disrupting activity, we further 
evaluated the anti-vascular activity of compound 16f. The HUVECs culture assays were 
performed to assess the ability of 16f to inhibit HUVECs migration which is the key 
step to generate new blood vessels. As shown in Figure 9A, the untreated cells migrated 
to fill the area that was initially scraped after 24 h. In contrast, 16f significantly inhibited 
the HUVEC migration in a dose-dependent manner.  
Then we further assessed the anti-vascular activity of 16f in a tube formation assay. 
After being seeded on Matrigel, HUVECs formed the capillary-like tubules with 
multicentric junctions. After exposure to 16f at 10, 20, and 40 nM for 6 h, the capillary-
like tubes were interrupted in different levels (Figure 9B). These results showed that 
compound 16f effectively has an effect on tubule-like disruption of HUVECs. 
The antiproliferative activity of 16f against HUVECs was also determined by an 
MTT assay to exclude the possibility that the anti-vascular activity of 16f was due to a 
cytotoxic action of 16f. The calculated IC50 value of 16f against HUVECs after a 24 h 
treatment was 0.126 ± 0.007 μM, which is higher than the concentration of 40 nM 
required for the obvious inhibition of cell migration and tube formation. These results 
indicate that 16f exhibited anti-vascular activity. 
 
Figure 9. Effects on the HUVECs migration and tube formation. A) Scratches were created with 
sterile 200 μL pipette and images were captured using phase contrast microscopy at 0 h and 24 h 
after treatments with 0, 10, 20 and 40 nM of 16f. B) Images depicting the formation of HUVEC 
capillary-like tubular network by treatments with 0, 10, 20 and 40 nM of 16f for 6 h. C) Histograms 
display the length of the scratches at 0 h and 24 h after treatments with 0, 10, 20 and 40 nM of 16f, 
***, P < 0.001 vs control group. 
 
2.9 In vivo antitumor activity of 16f 
To evaluate the in vivo antitumor activities of 16f, liver cancer allograft mouse model 
was established by subcutaneous inoculation of H22 cells into the right flank of mice. 
The tumor size and body weights of the mice were monitored and recorded every 2 
days. Paclitaxel (PTX), CA-4 and the disodium phosphate of CA-4 (CA-4P) were 
selected as the positive controls. As shown in Figure 10A and Figure 10B, 16f at the 
dose of 20 mg/kg per day significantly decreased the tumor volume. Obviously, the 
reduction in tumor weight reached 65.8% at dose of 20 mg/kg per day (i.v.) of 16f, 
which was slightly less potent than PTX (72.7% at a dose of 6 mg/kg per 2 days). 
Particularly, 16f at the dose of 20 mg/kg displayed more potent antitumor activity than 
CA-4 (inhibition rate: 50.9% at 20 mg/kg) or CA-4P (inhibition rate: 62.7% at 20 mg/kg) 
(Figure 10D). Moreover, 16f did not significantly affected body weight even at the 
doses of 20 mg/kg, while treatment with PTX at a dose of 6 mg/kg per 2 days led to a 
significant influence on body weight (Figure 10C). Thus, compound 16f is worthy of 
further investigation for the treatment of cancers. 
 
 
Figure 10. 16f inhibited liver cancer allograft growth in vivo. After administered with vehicle, PTX 
(6 mg/kg per 2 days, group 2), CA-4 (20 mg/kg per day), CA-4P (20 mg/kg per day), 16f (10 mg/kg 
per day), and 16f (20 mg/kg per day) for three weeks, the mice were sacrificed, and the tumors were 
weighed. A) The images of tumors from mice at 21 days after initiation of treatment. B) Tumor 
volume changes of mice during treatment. C) Body weight changes of mice during treatment. D) 
The weight of the excised tumors of each group. **P < 0.05, ***P < 0.001 vs control group. 
 
2.10 Molecular modelling studies 
To explain the binding modes of the most active compound 16f with tubulin, we 
performed a docking study of 16f into the colchicine binding pocket of tubulin (PDB: 
5lyj) by using the DOCK program in the Discovery Studio 3.0 software. As shown in 
figure 11A, 16f adopted a very similar positioning to the colchicine at the colchicine 
binding pocket. As displayed in figure 11B, the N-1 of pyridine moiety formed a critical 
hydrogen bond with residue Cys241 resembling that of the 4-methoxy group in 
compound 2a. Moreover, the hydroxy group of ring B formed two additional hydrogen 
bonds with Val181 and Asn258, which illustrated the vital role of the exposed hydroxyl 
group. 
  
 
Figure 11. Proposed binding model for 16f (violet) binding with tubulin (PDB code: 5lyj), and 
overlapping with colchicine (green) and compound 2a (yellow). 
 
3. Conclusion 
 In summary, we designed and synthesized a series of novel pyridine-chalcone 
derivatives as microtubule destabilizing agents, which may have some potential 
advantages over the reported chalcones.  
All compounds were evaluated for their anti-proliferative activities, and their 
detailed SARs were obtained. Compound 16f exhibited the most potent activities 
against five cancer cell lines with IC50 values ranging from 23 to 45 nM, which was 3-
fold more potent than parent compound 2a. Compared to chalcone derivatives without 
nitrogenous heterocycles, such as 2a and 2b, the introduction of pyridine moiety, which 
can be further prepared as the hydrochloride salts, provides an alternative method to 
improve the solubility of CBSIs. On the other hand, compound 16f has a promising 
application in development for its simpler processing than that of the quinoline-
chalcone derivatives in our previous study [20]. 
Besides, by using colchicine competition inhibition assay and molecular modelling 
studies, representative compound 16f was verified to bind to the colchicine binding site 
as microtubule-destabilizing agent with the IC50 value of 2.08 μM. Further mechanism 
studies demonstrated that 16f disrupted microtubule networks, arrested cell cycle at 
G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells in a dose-
dependent manner. Furthermore, the wound healing and tube formation assays also 
identified 16f as a novel vascular disrupting agent. The most importantly, the in vivo 
antitumor experiments displayed that 16f effectively suppressed the tumor volume and 
reduced tumor weight by 65.8% at the dose of 20 mg/kg per day (i.v.), which was more 
potent than control compound CA-4 (inhibition rate: 50.9% at 20 mg/kg) or CA-4P 
(inhibition rate: 62.7% at 20 mg/kg). Collectively, the present study demonstrates that 
pyridine-chalcone derivative 16f represents a novel class of anti-tubulin agent with 
potent anti-vascular and antitumor activities and deserves further investigation. 
 
EXPERIMENTAL SECTION 
4.1. Chemistry  
4.1.1. General 
Most chemicals and solvents were purchased from commercial sources. Further 
purification and drying by standard methods were employed when necessary. 1H NMR 
and 13C NMR spectra were recorded on Bruker-300 spectrometers in the indicated 
solvents (TMS as internal standard). Data are reported as follows: chemical shift in ppm 
(d), multiplicity (s =singlet, d =doublet, t =triplet, q =quartet, brs = broad singlet, m 
=multiplet), coupling constant (Hz), and integration. High Resolution Mass 
measurement was performed on Agilent QTOF 6520 mass spectrometer with electron 
spray ionization (ESI) as the ion source. Flash column chromatography was carried out 
using commercially available silica gel (200-300 mesh) under pressure. 
 
4.1.2 Synthesis of intermediate 5 
To a solution of 2,6-dichloroisonicotinic acid (10 g, 52 mmol) in 50 mL anhydrous 
THF under nitrogen atmosphere at 0 °C was added C2H5MgBr in diethyl ether (2 M, 
80 mL, 160 mmol). After stirring for 2 h, the reaction was quenched by NH4Cl aqueous, 
and extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to provide the 
crude product, which was purified by column chromatography with petroleum/ethyl 
acetate (4:1) to give intermediate 5 as white solid (9.0 g, 85.1 %).1H NMR (300 MHz, 
CDCl3) δ 7.67 (s, 2H), 2.96 (q, J = 7.1 Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H), 13C NMR (75 
MHz, CDCl3) δ 197.15, 151.85, 147.70, 120.91, 32.64, 7.54; ESI-MS m/z: 202.9 
[M+Na]+ 225.9. 
4.1.3 Synthesis of intermediate 6 
To a solution of 5 (6 g, 29.4 mmol) in anhydrous toluene was added DBU (12.43 mL, 
88.2 mmol), 2-bromoethanol (10.42 mL, 147 mmol). The mixture was stirred at 80 °C 
overnight. Then the solvent was removed in vacuo, and the residue was diluted by H2O, 
and extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to provide the 
crude product, which was purified by column chromatography with petroleum/ethyl 
acetate (40:1) to give intermediate 6 as colorless oil (6 g, 83.2 %).1H NMR (300 MHz, 
CDCl3) δ 7.33 (s, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.78 (t, J = 6.9 Hz, 2H), 1.85 (q, J = 7.6 
Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H); ESI-MS m/z: 247.0 [M+Na]+ 270.0. 
4.1.4 Synthesis of intermediate 9a 
To a solution of 6 (2.5 g, 10.1 mmol) in anhydrous MeOH was added sodium 
methoxide solid (5.45 g, 101 mmol). The mixture was stirred at 60 °C in sealed tube 
overnight. Then the reaction was quenched by H2O, the solvent was removed in vacuo, 
and the residue was extracted with CH2Cl2 (3 × 20 mL). The combined organic layers 
were then washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo 
to provide the crude product, which was dissolved in MeOH, and concentrated 
hydrochloric acid (10 mL) was added. Then the mixture was stirred at room temperature 
for 2 h. Then, the solution was neutralized with 2 M NaOH aqueous to pH 7, and 
extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to provide the 
crude product, which was purified by column chromatography with petroleum/ethyl 
acetate (4:1) to give intermediate 9a as yellow solid (1.5 g, 79.1%).1H NMR (300 MHz, 
CDCl3) δ 7.33 (s, 1H), 7.09 (s, 1H), 3.98 (s, 3H), 2.93 (q, J = 7.1 Hz, 2H), 1.25 - 1.17 
(m, 3H); ESI-MS m/z: 199.0 [M+Na]+ 222.0. 
4.1.5 Synthesis of intermediate 9b 
To a solution of 6 (5 g, 20.2 mmol) in anhydrous MeOH was added sodium 
methoxide solid (10.89 g, 202 mmol). The mixture was stirred at 100 °C in sealed tube 
overnight. Then the reaction was quenched by H2O, the solvent was removed in vacuo, 
and the residue was extracted with CH2Cl2 (3 × 20 mL). The combined organic layers 
were then washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo 
to provide the crude product, which was dissolved in MeOH, and concentrated 
hydrochloric acid (10 mL) was added. Then the mixture was stirred at room temperature 
for 2 h. Then, the solution was neutralized with 2 M NaOH aqueous to pH 7, and 
extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to provide the 
crude product, which was purified by column chromatography with petroleum/ethyl 
acetate (4:1) to give intermediate 9b as yellow solid (3.2 g, 81.1 %).1H NMR (300 MHz, 
CDCl3) δ 6.75 (s, 2H), 3.95 (s, 6H), 2.92 (q, J = 6.5 Hz, 2H), 1.20 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 200.01, 164.01, 148.70, 99.41, 53.89, 32.44, 7.85; ESI-
MS m/z: 195.0 [M+Na]+ 218.0. 
4.1.6 Synthesis of intermediate 10 
To a solution of 6 (1.5 g, 4.1 mmo) in anhydrous DCM was added HOBt (1.3 g, 4.8 
mmol), EDCI (1.8 g, 4.8 mmol), Et3N (0.62 g, 6.15 mmol) and N-methoxymethanamine 
(1.2 g, 6.6 mmol). The mixture was stirred at room temperature for 2 h. The precipitate 
was filtered and the filtrate was removed under vacuum. The resulting mixture was then 
purified by flash column chromatography with petroleum/ethyl acetate (4:1) to give 
intermediate 10 as white solid (1.6 g, 85.1 %). 1H NMR (300 MHz, CDCl3) δ 7.50 (s, 
2H), 3.58 (s, 3H), 3.37 (s, 3H); ESI-MS m/z: 233.9 [M+Na]+ 256.9. 
4.1.7 Synthesis of intermediate 11 
To a solution of 10 (1.1 g, 4.68 mmol) in 10 ml anhydrous THF under nitrogen 
atmosphere at 0 °C was added CH3MgBr in diethyl ether (3 M, 2.34 mL, 4.80 mmol). 
After stirring for 2 h, the reaction was quenched by NH4Cl aqueous, and extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layers were then washed with brine, dried 
over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which 
was purified by column chromatography with petroleum/ethyl acetate (4:1) to give 
intermediate 11 as white solid (0.820 g, 92.1 %).1H NMR (300 MHz, CDCl3) δ 7.69 (s, 
2H), 2.64 (s, 3H); ESI-MS m/z: 188.9 [M+Na]+ 211.9. 
4.1.8 Synthesis of intermediate 14 
To a solution of 11 (1.2 g，6.32 mmol)in anhydrous toluene was added DBU (2.67 
mL , 19.0 mmol), 2-bromoethanol (2.24 mL, 31.6 mmol). The mixture was stirred at 
80 °C overnight. Then the solvent was removed in vacuo, and the residue was diluted 
by H2O, and extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were 
then washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
provide the crude product 12 as colorless oil (1.25 g, 83.1%). To a solution of 12 (1.25 
g, 5.05 mmol) in anhydrous MeOH was added sodium methoxide (2.72 g, 50.5 mmol). 
The mixture was stirred at 100 °C in sealed tube overnight. Then the reaction was 
quenched by H2O, the solvent was removed in vacuo, and the residue was extracted 
with CH2Cl2 (3 × 20 mL). The combined organic layers were then washed with brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, 
which was dissolved in MeOH, and concentrated hydrochloric acid (10 ml) was added. 
Then the mixture was stirred at room temperature for 2 h. Then, the solution was 
neutralized with 2 M NaOH aqueous to pH 7, and extracted with CH2Cl2 (3 × 20 mL). 
The combined organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo to provide the crude product, which was purified 
by column chromatography with petroleum/ethyl acetate (4:1) to give intermediate 14 
as white solid (0.8 g, 81.1 %).1H NMR (300 MHz, CDCl3) δ 6.74 (s, 2H), 3.95 (s, 6H), 
2.55 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 212.48, 164.06, 148.74, 99.70, 53.94, 27.01; 
ESI-MS m/z: 181.0 [M+Na]+ 204. 
4.1.9 The procedure for the preparation of 15a-f and 16a-f. 
To a stirred solution of ketone (0.28 mmol) and aldehyde (0.28 mmol) in anhydrous 
EtOH, NaOH (55.1 mg, 1.38 mmol) was slowly added at room temperature. After 
stirring for 3 h, the reaction mixture was concentrated and extracted with CH2Cl2 (3 × 
20 mL). The combined organic layers were then washed with brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which was 
purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 
corresponding pure compounds 15a-f and 16a-f. 
4.1.9.1 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (15a). 
Yellow solid, yield 76.2%. 1H NMR (300 MHz, CDCl3) δ 7.63 (d, J = 15.7 Hz, 1H), 
7.45 (d, J = 8.6 Hz, 2H), 7.07 (d, J = 15.7 Hz, 1H), 6.81 (d, J = 8.6 Hz, 2H), 6.64 (s, 
2H), 3.84 (s, 6H), 3.73 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 189.92, 163.88, 162.04, 
150.74, 146.20, 130.47, 127.21, 119.61, 114.50, 99.85, 55.43, 53.89; HR-MS (ESI) m/z: 
calcd for C17H18NO4 [M+H]
+ 300.1230 found 300.1229. 
4.1.9.2 (E)-3-(3,4-dimethoxyphenyl)-1-(2,6-dimethoxypyridin-4-yl)prop-2-en-1-one 
(15b). Yellow solid, yield 72.3%. 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 15.7 Hz, 
1H), 7.09 – 6.98 (m, 3H), 6.75 (d, J = 8.3 Hz, 1H), 6.63 (s, 2H), 3.83 (s, 6H), 3.81 (s, 
3H), 3.79 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 189.87, 163.85, 151.84, 150.69, 149.31, 
146.50, 127.43, 123.71, 119.76, 111.11, 109.96, 99.86, 56.00, 55.96, 53.89. HR-MS 
(ESI) m/z: calcd for C18H20NO5 [M+H]
+ 330.1336, found 330.1331. 
4.1.9.3 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
(15c). Yellow solid, yield 83.7%. 1H NMR (300 MHz, CDCl3) δ 7.57 (d, J = 15.7 Hz, 
1H), 7.10 (s, 1H), 6.72 (s, 2H), 6.65 (s, 2H), 3.86 (s, 6H), 3.80 (s, 6H), 3.78 (s, 3H), 13C 
NMR (75 MHz, CDCl3) δ 189.88, 163.89, 153.51, 150.47, 146.49, 140.88, 129.87, 
121.20, 105.88, 99.92, 61.01, 56.25, 53.92; HR-MS (ESI) m/z: calcd for C19H22NO6 
[M+H]+ 360.1442, found 360.1440. 
4.1.9.4 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(4-(methylthio)phenyl)prop-2-en-1-one 
(15d). Yellow solid, yield 77.6%. 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 15.7 Hz, 
1H), 7.53 (d, J = 8.1 Hz, 2H), 7.30 (s, 1H), 7.24 (d, J = 5.0 Hz, 2H), 6.77 (s, 2H), 3.97 
(s, 6H), 2.52 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 205.60, 163.92, 156.40, 150.51, 
145.81, 128.97, 125.92, 120.80, 99.86, 98.74, 53.93, 15.06. HR-MS (ESI) m/z: calcd 
for C17H18NO3S [M+H]
+ 316.1002, found 316.0998. 
4.1.9.5 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-
1-one (15e). Yellow solid, yield 57.3%. 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 15.7 
Hz, 1H), 7.25 (d, J = 3.0 Hz, 1H), 7.21 (s, 1H), 7.15 – 7.11 (m, 1H), 6.88 (d, J = 8.3 Hz, 
1H), 6.76 (s, 2H), 5.68 (s, 1H), 3.97 (s, 6H), 3.95 (s, 3H), 13C NMR (75 MHz, CDCl3) 
δ 163.60, 163.36, 161.07, 153.08, 152.69, 149.77, 136.54, 106.04, 105.03, 99.33, 98.74, 
98.03, 56.15, 53.65. HR-MS (ESI) m/z: calcd for C17H18NO5 [M+H]
+316.1179, found 
316.1174. 
4.1.9.6 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-1-
one (15f). White solid, yield 63.7%. 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 15.7 
Hz, 1H), 7.24 (t, J = 11.2 Hz, 2H), 7.05 (d, J = 15.7 Hz, 1H), 6.85 (t, J = 8.4 Hz, 1H), 
6.63 (s, 2H), 3.85 (s, 6H), 3.81 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 189.61, 163.93, 
154.05, 150.36, 150.04 (d, J = 24.0 Hz), 147.85, 146.01, 144.95, 127.69, 126.31, 123.80, 
120.75 (d, J = 228.8 Hz), 115.15, 114.90 (d, J = 18.8 Hz), 113.21, 99.83, 56.27, 53.91; 
HR-MS (ESI) m/z: calcd for C17H17FNO4 [M+H]
+ 318.1136, found 318.1140. 
4.1.9.7 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(4-methoxyphenyl)-2-methylprop-2-en-1-
one (16a). Yellow solid, yield 78.7%. 1H NMR (300 MHz, CDCl3) δ 7.40 (d, J = 8.4 
Hz, 2H), 7.23 (s, 1H), 6.96 – 6.89 (m, 2H), 6.46 (s, 2H), 3.96 (s, 6H), 3.85 (s, 3H), 2.23 
(s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.33, 162.70, 159.85, 151.75, 144.55, 133.53, 
131.43, 127.49, 113.52, 100.07, 54.86, 53.29, 12.99. HR-MS (ESI) m/z: calcd for 
C20H24NO6 [M+H]
+ 374.1598, found 313.1596. 
4.1.9.8 (E)-3-(3,4-dimethoxyphenyl)-1-(2,6-dimethoxypyridin-4-yl)-2-methylprop-2-
en-1-one (16b). Yellow solid, yield 86.9%. 1H NMR (300 MHz, CDCl3) δ 7.22 (s, 1H), 
7.07 (d, J = 8.0 Hz, 1H), 6.95 – 6.89 (m, 2H), 6.46 (s, 2H), 3.96 (s, 6H), 3.93 (s, 3H), 
3.90 (s, 3H), 2.26 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.26, 162.72, 151.73, 149.49, 
148.25, 144.67, 133.82, 127.73, 123.30, 112.58, 110.41, 100.07, 55.46, 53.30, 13.07. 
HR-MS (ESI) m/z: calcd for C19H22NO5 [M+H]
+ 344.1492, found 313.1493. 
4.1.9.9 (E)-1-(2,6-dimethoxypyridin-4-yl)-2-methyl-3-(3,4,5-trimethoxyphenyl)prop-2-
en-1-one (16c). Yellow solid, yield 85.3%. 1H NMR (300 MHz, CDCl3) δ 7.19 (s, 1H), 
6.64 (s, 2H), 6.47 (s, 2H), 3.97 (s, 6H), 3.89 (s, 3H), 3.88 (s, 6H), 2.25 (s, 3H), 13C NMR 
(75 MHz, CDCl3) δ 197.17, 162.76, 152.59, 151.40, 144.43, 138.52, 134.97, 130.29, 
106.93, 100.10, 60.47, 55.74, 53.31, 13.16. HR-MS (ESI) m/z: calcd for C18H20NO4 
[M+H]+ 313.1387, found 313.1385. 
4.1.9.10 (E)-1-(2,6-dichloropyridin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-
methylprop-2-en-1-one (16d). Yellow solid, yield 75.1%. 1H NMR (300 MHz, CDCl3) 
δ 7.13 (s, 1H), 7.09 (s, 1H), 7.04 (s, 1H), 6.96 (d, J = 9.5 Hz, 1H), 6.89 (d, J = 8.8 Hz, 
1H), 6.77 (s, 1H), 3.95 (s, 3H), 2.24 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 198.78, 
160.43, 141.55, 135.76, 131.55, 126.42, 123.28, 120.95, 118.52, 111.52, 107.06, 103.53, 
55.57, 15.01. HR-MS (ESI) m/z: calcd for C16H14Cl2NO3 [M+H]
+ 338.0345, found 
338.0352. 
4.1.9.11 (E)-1-(2-chloro-6-methoxypyridin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-
methylprop-2-en-1-one (16e). Yellow solid, yield 65.2%. 1H NMR (300 MHz, DMSO-
d6) δ 9.24 (s, 1H), 7.19 (s, 1H), 7.11 (s, 1H), 7.06 (s, 1H), 7.00 (s, 2H), 6.93 (s, 1H), 
3.91 (s, 3H), 3.82 (s, 3H), 2.15 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.26, 162.70, 
147.23, 144.57, 136.24, 133.68, 128.15, 127.51, 126.98, 126.69, 124.14, 115.28, 110.85, 
100.06, 55.51, 53.30, 12.86. HR-MS (ESI) m/z: calcd for C17H17ClNO4 [M+H]
+ 
334.0841, found 334.0834. 
4.1.9.12 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(3-hydroxy-4-methoxyphenyl)-2-
methylprop-2-en-1-one (16f). Yellow solid, yield 75.3%. 1H NMR (300 MHz, CDCl3) 
δ 7.18 (s, 1H), 7.08 (d, J = 2.1 Hz, 1H), 6.97 – 6.92 (m, 1H), 6.87 (d, J = 8.5 Hz, 1H), 
6.45 (s, 2H), 5.64 (s, 1H), 3.96 (s, 6H), 3.94 (s, 3H), 2.23 (s, 3H), 13C NMR (75 MHz, 
CDCl3) δ 162.72, 151.65, 146.91, 144.95, 144.51, 128.36, 127.81, 127.44, 122.83, 
115.47, 109.87, 100.10, 55.49, 53.30, 13.01. HR-MS (ESI) m/z: calcd for C18H20NO5 
[M+H]+ 330.1336, found 330.1332. 
4.1.10 The procedure for the preparation of 18a-i. 
To a stirred solution of ketone 9b (50 mg, 0.34 mmol) and aldehyde (0.34 mmol) in 
anhydrous EtOH, piperidine (144.9 mg, 1.72 mmol) was slowly added. After stirring 
for 10 h at 80 °C, the reaction mixture was concentrated and extracted with CH2Cl2 (3 
× 20 mL). The combined organic layers were then washed with brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which was 
purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 
corresponding pure compounds 18a-i. 
4.1.10.1 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1H-indol-3-yl)-2-methylprop-2-en-1-
one (18a). Yellow solid, yield 85.9%. 1H NMR (300 MHz, CDCl3) δ 8.74 (s, 1H), 7.70 
(s, 1H), 7.65 (d, J = 2.9 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.29 
(d, J = 7.5 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 6.51 (s, 2H), 3.98 (s, 6H), 2.28 (s, 3H), 
13C NMR (75 MHz, DMSO-d6) δ 195.46, 162.62, 153.39, 137.13, 135.76, 129.10, 
128.89, 127.15, 122.59, 120.57, 117.59, 112.13, 111.21, 99.95, 53.52, 13.77. HR-MS 
(ESI) m/z: calcd for C19H19N2O3[M+H]
+ 323.1390, found 323.1388. 
4.1.10.2 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(5-methoxy-1H-indol-3-yl)-2-
methylprop-2-en-1-one (18b). Yellow solid, yield 77.9%. 1H NMR (300 MHz, CDCl3) 
δ 8.66 (s, 1H), 7.63 (d, J = 10.0 Hz, 2H), 7.32 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 10.9 Hz, 
2H), 6.52 (s, 2H), 3.97 (s, 6H), 3.84 (s, 3H), 2.26 (s, 3H), 13C NMR (75 MHz, CDCl3) 
δ 196.85, 163.22, 155.22, 136.87, 131.52, 130.81, 130.53, 128.26, 127.16, 113.21, 
112.15, 110.40, 101.08, 100.70, 55.92, 53.78, 14.29. HR-MS (ESI) m/z: calcd for 
C20H21N2O4[M+H]
+ 353.1496, found 353.1497. 
4.1.10.3 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(6-methoxy-1H-indol-3-yl)-2-
methylprop-2-en-1-one (18c). Yellow solid, yield 78.3%. 1H NMR (300 MHz, CDCl3) 
δ 8.62 (s, 1H), 7.64 (s, 1H), 7.53 (d, J = 2.8 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 6.89 (d, 
J = 2.1 Hz, 1H), 6.85 (dd, J = 8.7, 2.2 Hz, 1H), 6.49 (s, 2H), 3.97 (s, 6H), 3.85 (s, 3H), 
2.25 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 196.50, 162.71, 156.89, 152.44, 148.19, 
136.68, 130.68, 125.14, 121.14, 118.81, 112.85, 110.56, 100.05, 94.23, 55.18, 53.32, 
13.67. HR-MS (ESI) m/z: calcd for C20H21N2O4[M+H]
+ 353.1496, found 353.1499. 
4.1.10.4 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(5-fluoro-1H-indol-3-yl)-2-methylprop-
2-en-1-one (18d). Yellow solid, yield 66.5%. 1H NMR (300 MHz, CDCl3) δ 8.76 (s, 
1H), 7.68 (s, 1H), 7.56 (s, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.17 (d, J = 9.2 Hz, 1H), 7.04 
(d, J = 9.2 Hz, 1H), 6.49 (s, 2H), 3.99 (s, 6H), 2.26 (s, 3H), 13C NMR (75 MHz, DMSO-
d6) δ 196.03, 163.11, 153.58, 137.14, 132.90, 131.22, 129.64, 113.88 (d, J = 186.8 Hz), 
113.75, 111.94, 111.39, 111.03, 103.63, 103.31, 100.58, 53.97, 14.40. HR-MS (ESI) 
m/z: calcd for C19H18FN2O3[M+H]
+ 341.1296, found 341.1298. 
4.1.10.5 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(6-fluoro-1H-indol-3-yl)-2-methylprop-
2-en-1-one (18e). Yellow solid, yield 66.5%. 1H NMR (300 MHz, CDCl3) δ 8.73 (s, 
1H), 7.62 (s, 2H), 7.47 – 7.41 (m, 1H), 7.11 (d, J = 8.9 Hz, 1H), 7.00 – 6.92 (m, 1H), 
6.50 (s, 2H), 3.98 (s, 6H), 2.26 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.00, 163.24, 
152.69, 136.41, 131.81, 126.82, 124.02, 119.67, 119.54, 113.30, 110.08 (d, J = 241.5 
Hz), 109.76, 100.56, 98.05, 97.70, 53.84, 14.23. HR-MS (ESI) m/z: calcd for 
C19H18FN2O3[M+H]
+ 341.1296, found 341.1296. 
4.1.10.6 (E)-3-(5-chloro-1H-indol-3-yl)-1-(2,6-dimethoxypyridin-4-yl)-2-methylprop-
2-en-1-one (18f). Yellow solid, yield 73.5%. 1H NMR (300 MHz, CDCl3) δ 8.68 (s, 
1H), 7.66 (s, 1H), 7.55 (s, 1H), 7.49 (s, 1H), 7.35 (d, J = 8.8 Hz, 2H), 6.49 (s, 2H), 3.99 
(s, 6H), 2.26 (s, 3H), 13C NMR (75 MHz, DMSO-d6) δ 196.10, 163.10, 153.50, 136.78, 
134.79, 130.95, 130.13, 128.83, 125.63, 123.06, 117.75, 114.21, 111.51, 100.64, 54.00, 
14.48. HR-MS (ESI) m/z: calcd for C19H18ClN2O3[M+H]
+ 357.1000, found 357.1001. 
4.1.10.7 (E)-3-(6-chloro-1H-indol-3-yl)-1-(2,6-dimethoxypyridin-4-yl)-2-methylprop-
2-en-1-one (18g). Yellow solid, yield 53.7%. 1H NMR (300 MHz, CDCl3) δ 8.75 (s, 
1H), 7.64 – 7.58 (m, 2H), 7.42 (s, 1H), 7.16 (dd, J = 8.4, 1.9 Hz, 1H), 6.74 (s, 1H), 6.50 
(s, 2H), 3.98 (s, 6H), 2.26 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 200.37, 163.25, 152.62, 
136.18, 135.85, 131.91, 129.38, 127.01, 126.00, 121.85, 119.63, 113.33, 111.43, 100.56, 
53.84, 14.27. HR-MS (ESI) m/z: calcd for C19H18ClN2O3[M+H]
+ 357.1000, found 
357.1002. 
4.1.10.8 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1H-indol-5-yl)-2-methylprop-2-en-1-
one (18h). Yellow solid, yield 86.1%. 1H NMR (300 MHz, CDCl3) δ 8.37 (s, 1H), 7.73 
(s, 1H), 7.43 (d, J = 6.5 Hz, 1H), 7.27 (d, J = 4.7 Hz, 3H), 6.57 (s, 2H), 6.43 (s, 1H), 
3.97 (s, 6H), 2.25 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.54, 162.79, 151.63, 142.75, 
135.59, 135.24, 127.13, 126.95, 124.45, 121.29, 120.41, 111.64, 100.77, 100.25, 53.34, 
13.52. HR-MS (ESI) m/z: calcd for C19H19N2O3[M+H]
+ 323.1390, found 323.1395. 
4.1.10.9 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1H-indol-6-yl)-2-methylprop-2-en-1-
one (18i). Yellow solid, yield 56.3%. 1H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 7.77 
(s, 1H), 7.46 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 1.7 Hz, 1H), 7.23 (s, 1H), 
6.58 (s, 1H), 6.50 (s, 2H), 3.96 (s, 6H), 2.32 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 
198.18, 163.23, 152.64, 147.59, 136.14, 133.51, 128.02, 127.27, 125.37, 124.62, 
123.51, 111.15, 103.38, 100.61, 53.78, 13.59. HR-MS (ESI) m/z: calcd for 
C19H19N2O3[M+H]
+ 323.1390, found 323.1393. 
4.1.11 (E)-1-(2,6-dimethoxypyridin-4-yl)-2-methyl-3-(1-methyl-1H-indol-3-yl)prop-2-
en-1-one (19a). To a solution of 18a (90 mg, 0.28 mmol) in anhydrous DMF was added 
NaH (10 mg, 0.42 mmol), MeI (52 mg, 0.36 mmol). After stirring at room temperature 
for 2 h, the mixture was diluted with water and extracted with ethyl acetate (3 × 20 mL). 
The combined organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo to provide the crude product, which was purified 
by column chromatography with petroleum/ethyl acetate (4:1) to give the 19a as yellow 
solid (70 mg, 78.02 %). 1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.52 (s, 2H), 7.34 
(d, J = 12.3 Hz, 2H), 7.22 (d, J = 7.4 Hz, 1H), 6.53 – 6.45 (m, 2H), 3.98 (s, 6H), 3.90 
(s, 3H), 2.27 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 196.82, 163.19, 153.14, 137.08, 
136.60, 131.33, 130.09, 128.26, 123.15, 120.97, 118.66, 111.90, 109.72, 100.56, 53.82, 
33.50, 14.24. HR-MS (ESI) m/z: calcd for C20H21N2O3[M+H]
+ 337.1547, found 
337.1544. 
4.1.12 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1-ethyl-1H-indol-3-yl)-2-methylprop-2-
en-1-one (19b). To a solution of 18a (90 mg, 0.28 mmol) in anhydrous DMF was added 
NaH (10 mg, 0.42 mmol), iodoethane (56.6 mg, 0.36 mmol). After stirring at room 
temperature for 2 h, the mixture was diluted with water and extracted with ethyl acetate 
(3 × 20 mL). The combined organic layers were then washed with brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which was 
purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 19b 
as yellow solid (60 mg, 72.3.2 %). 1H NMR (300 MHz, CDCl3) δ 7.70 (s, 1H), 7.57 (s, 
1H), 7.53 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.31 (d, J = 7.3 Hz, 1H), 7.18 (d, J = 7.4 Hz, 
1H), 6.49 (s, 2H), 4.27 (d, J = 7.3 Hz, 2H), 3.97 (s, 6H), 2.27 (s, 3H), 1.54 (s, 3H), 13C 
NMR (75 MHz, CDCl3) δ 196.85, 163.19, 153.17, 137.19, 135.63, 130.03, 129.67, 
128.47, 123.04, 120.93, 118.80, 112.02, 109.81, 100.55, 53.82, 41.77, 15.34, 14.26. 
HR-MS (ESI) m/z: calcd for C21H23N2O3[M+H]
+ 351.1703, found 351.1699. 
4.1.13 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1-(hydroxymethyl)-1H-indol-3-yl)-2-
methylprop-2-en-1-one (19c). To a solution of 18a (100 mg, 0.31 mmol) in anhydrous 
EtOH was added HCHO (37% in water, 1 mL), NaOH (6 N, 2 mL). After stirring at 
80 °C for 2 h, the reaction mixture was concentrated and extracted with CH2Cl2 (3 × 20 
mL). The combined organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo to provide the crude product, which was purified 
by column chromatography with petroleum/ethyl acetate (4:1) to give the 19c as yellow 
solid (60 mg, 55.04 %). 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 4.6 Hz, 2H), 7.50 
(d, J = 8.0 Hz, 2H), 7.31 - 7.18 (m, 2H), 6.43 (s, 2H), 5.69 (s, 2H), 3.95 (s, 6H), 2.21 
(s, 3H), 13C NMR (75 MHz, CDCl3) δ 197.24, 163.20, 152.62, 136.95, 135.47, 131.20, 
129.64, 128.77, 123.64, 121.61, 118.85, 113.06, 110.12, 100.53, 70.40, 53.83, 14.28. 
HR-MS (ESI) m/z: calcd for C20H21N2O4[M+H]
+ 353.1496, found 353.1492. 
4.1.14 (E)-3-(1-acetyl-1H-indol-3-yl)-1-(2,6-dimethoxypyridin-4-yl)-2-methylprop-2-
en-1-one (19d). 
To a solution of 18a (100 mg, 0.31 mmol) in anhydrous DCM was added NaOH (31 
mg, 0.78 mmol), acetylchloride (36.5 mg, 0.47 mmol). After stirring at room 
temperature for 2 h, the mixture was quenched with water and extracted with ethyl 
acetate (3 × 20 mL). The combined organic layers were then washed with brine, dried 
over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which 
was purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 
19d as yellow solid (80 mg, 70.80 %). 1H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 8.2 
Hz, 1H), 7.73 (s, 1H), 7.50 – 7.39 (m, 3H), 7.34 (d, J = 7.6 Hz, 1H), 6.52 (s, 2H), 3.98 
(s, 6H), 2.74 (s, 3H), 2.31 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 196.80, 168.48, 163.34, 
151.68, 135.82, 133.87, 129.72, 126.22, 125.72, 124.21, 118.72, 117.84, 116.61, 100.64, 
53.86, 24.14, 14.74. HR-MS (ESI) m/z: calcd for C21H21N2O4[M+H]
+ 365.1496, found 
365.1495. 
4.1.15 (E)-1-(2,6-dimethoxypyridin-4-yl)-3-(1-(furan-2-carbonyl)-1H-indol-3-yl)-2-
methylprop-2-en-1-one (19e). 
To a solution of 18a (100 mg, 0.31 mmol) in anhydrous DCM was added NaOH (31 
mg, 0.78 mmol), 2-furoyl chloride (61.3 mg, 0.47 mmol). After stirring at room 
temperature for 2 h, the mixture was quenched with water and extracted with ethyl 
acetate (3 × 20 mL). The combined organic layers were then washed with brine, dried 
over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which 
was purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 
19e as yellow solid (92 mg, 71.32 %). 1H NMR (300 MHz, CDCl3) δ 8.47 (d, J = 8.2 
Hz, 1H), 8.39 (s, 1H), 7.77 (s, 1H), 7.52 (d, J = 5.1 Hz, 2H), 7.42 (d, J = 7.8 Hz, 1H), 
7.36 (d, J = 7.4 Hz, 1H), 7.26 (s, 1H), 6.70 (s, 1H), 6.53 (s, 2H), 3.99 (s, 6H), 2.32 (s, 
3H), 13C NMR (75 MHz, CDCl3) δ 211.32, 196.82, 163.35, 153.37, 151.78, 146.78, 
136.09, 135.71, 134.11, 129.54, 127.20, 125.99, 124.54, 121.43, 118.66, 117.97, 116.68, 
112.74, 100.66, 53.85, 14.62. HR-MS (ESI) m/z: calcd for C24H21N2O5[M+H]
+ 
417.1445, found 417.1447. 
4.1.16 (E)-3-(1-benzoyl-1H-indol-3-yl)-1-(2,6-dimethoxypyridin-4-yl)-2-methylprop-
2-en-1-one (19f). 
To a solution of 18a (100 mg, 0.31 mmol) in anhydrous DCM was added NaOH (31 
mg, 0.78 mmol), benzoyl chloride (66.1 mg, 0.47 mmol). After stirring at room 
temperature for 2 h, the mixture was quenched with water and extracted with ethyl 
acetate (3 × 20 mL). The combined organic layers were then washed with brine, dried 
over anhydrous Na2SO4, and concentrated in vacuo to provide the crude product, which 
was purified by column chromatography with petroleum/ethyl acetate (4:1) to give the 
19f as yellow solid (100 mg, 75.76 %).1H NMR (300 MHz, CDCl3) δ 8.34 (d, J = 8.2 
Hz, 1H), 7.83 - 7.77 (m, 2H), 7.62 (dq, J = 14.8, 7.4 Hz, 4H), 7.52 – 7.36 (m, 4H), 6.50 
(s, 2H), 3.98 (s, 6H), 2.16 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 196.76, 168.49, 163.33, 
151.73, 135.75, 133.94, 133.86, 132.62, 129.98, 129.32, 128.86, 128.17, 125.95, 
124.43, 118.80, 117.24, 116.39, 100.63, 53.85, 14.54. HR-MS (ESI) m/z: calcd for 
C26H23N2O4[M+H]
+ 427.1652, found 427.1653. 
4.1.17 (E)-1-(2,6-dimethoxypyridin-4-yl)-2-methyl-3-(1-methyl-1H-indol-5-yl)prop-2-
en-1-one (19g). 
To a solution of 18h (90 mg, 0.28 mmol) in anhydrous DMF was added NaH (10 mg, 
0.42 mmol), MeI (52 mg, 0.36 mmol). After stirring at room temperature for 2 h, the 
mixture was diluted with water and extracted with ethyl acetate (3 × 20 mL). The 
combined organic layers were then washed with brine, dried over anhydrous Na2SO4, 
and concentrated in vacuo to provide the crude product, which was purified by column 
chromatography with petroleum/ethyl acetate (4:1) to give the 19g as yellow solid (75 
mg, 83.59 %).1H NMR (300 MHz, CDCl3) δ 7.77 (s, 1H), 7.46 (s, 1H), 7.33 (s, 2H), 
7.10 (d, J = 3.1 Hz, 1H), 6.53 (d, J = 3.2 Hz, 1H), 6.49 (s, 2H), 3.96 (s, 6H), 3.82 (s, 
3H), 2.32 (s, 3H), 13C NMR (75 MHz, CDCl3) δ 192.51, 163.19, 137.20, 130.75, 129.70, 
128.53, 126.42, 123.03, 121.78, 120.93, 118.78, 109.82, 103.22, 100.55, 53.82, 41.76, 
14.26. HR-MS (ESI) m/z: calcd for C20H21N2O3[M+H]
+ 337.1547, found 337.1544. 
4.2 Pharmacology 
4.2.1 In vitro antiproliferative assay 
Cells were purchased from Nanjing KeyGen Biotech Co. Ltd. (Nanjing, China). The 
cytotoxicity of the test compounds was determined using the MTT assay. Briefly, the 
cell lines were incubated at 37 °C in a humidified 5% CO2 incubator for 24 h in 96-
microwell plates. After medium removal, 100 mL of culture medium with 0.1% DMSO 
containing the test compounds at different concentrations was added to each well and 
incubated at 37 °C for another 72 h. The MTT (5 mg/mL in PBS) was added and 
incubated for another 4 h, the optical density was detected with a microplate reader at 
490 nm. The IC50 values were calculated according to the dose-dependent curves. All 
the experiments were repeated in at least three independent experiments.  
 
4.2.2 In vitro tubulin polymerization inhibitory assay 
An amount of 2 mg/mL tubulin (Cytoskeleton) was resuspended in PEM buffer 
containing 80 mM piperazine-N,N’-bis(2-ethanesulfonic acid) sequisodium salt PIPES 
(pH 6.9), 0.5 mM EGTA, 2 mM MgCl2, and 15% glycerol. Then the mixture was 
preincubated with tested compounds or vehicle DMSO on ice. PEG containing GTP 
was added to the final concentration of 3 mg/mL before detecting the tubulin 
polymerization reaction. After 30 min, the absorbance was detected by a 
spectrophotometer at 340 nm at 37 °C every 2 min for 60 min. The area under the curve 
was used to determine the concentration that inhibited tubulin polymerization by 50% 
(IC50), which was calculated with GraphPad Prism Software version 5.02. 
 
4.2.3 Competitive Inhibition Assays.  
The competitive binding activity of tested compounds was evaluated using a 
radiolabeled [3H]colchicine competition scintillation proximity (SPA) assay. In brief, 
0.08 μM [3H]colchicine was mixed with 16f (1 μM, 5 μM) or CA-4 (1 μM, 5 μM) and 
biotinylated porcine tubulin (0.5 μg) in a buffer of 100 μL containing 80 mM PIPES 
(pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2, and 1 mM GTP for 2 h at 37 °C. 
Then streptavidin-labeled SPA beads (80 μg) were added to each mixture. The 
radioactive counts were measured directly with a scintillation counter. 
 
4.2.4 Immunofluorescence Staining 
K562 cells or MDA-MB-231 cells were seeded into 6-well plates and then treated 
with vehicle control 0.1% DMSO, 16f (10, 20, 40 nM) or 16f (20, 40, 80 nM) 
respectively. The cells were fixed with 4% paraformaldehyde and then penetrated with 
PBS for three times. After blocking for 20 min by adding 50-100 μL goat serum albumin 
at room temperature, cells were incubated with a monoclonal antibody (anti-α-tubulin) 
at 37 °C for 2 h. Then the cells were washed three times by PBS following staining by 
fluorescence antibody and labeling of nuclei by 4,6-diamidino-2-phenylindole (DAPI). 
Cells were finally visualized using an LSM 570 laser confocal microscope (Carl Zeiss, 
Germany). 
   
4.2.5 Cell cycle analysis 
K562 cells were seeded into 6-well plates and incubated at 37 °C in a humidified 5% 
CO2 incubator for 24 h, and then treated with or without 16f at indicated concentrations 
for another 48 h. The collected cells were fixed by adding 70% ethanol at 4 °C for 12 
h. Subsequently, the cells were resuspended in PBS containing 100 mL RNase A and 
400 mL of propidium iodide for 30 min. The DNA content of the cells was measured 
using a FACS Calibur flow cytometer (Bectone Dickinson, San Jose, CA, USA). 
 
4.2.6 Cell apoptosis analysis 
After treatment with or without 16f at indicated concentrations for 48 h, the cells 
were washed twice in PBS, centrifuged and resuspended in 500 mL AnnexinV binding 
buffer. The cells were then harvested, washed and stained with 5 mL Annexin V-APC 
and 5 mL 7-AAD in the darkness for 15 min. Apoptosis was analyzed using a FACS 
Calibur flow cytometer (Bectone Dickinson, San Jose, CA, USA). 
 
4.2.7 Mitochondrial Membrane Potential Analysis 
After treatment with vehicle control 0.1% DMSO, 16f (10 nM, 20 nM, and 40 nM) 
for 24 h, the cells were washed in PBS and resuspended in 500 mL JC-1 incubation 
buffer at 37 °C for 15 min. The percentage of cells with healthy or collapsed 
mitochondrial membrane potentials was monitored by flow cytometry analysis 
(Bectone-Dickinson, San Jose, CA, USA). 
 
4.2.8 Wound healing assay 
K562 cells were grown in 6-well plates for 24 h. Scratches were made in confluent 
monolayers using 200 µL pipette tip. Then, wounds were washed twice with PBS to 
remove non-adherent cell debris. The media containing different concentrations (1, 2, 
4 nM) of the compound 16f were added to the petridishes. Cells which migrated across 
the wound area were photographed using phase contrast microscopy at 0 h and 24 h. 
The migration distance of cells migrated in to the wound area was measured manually. 
 
4.2.9 Tube formation assay 
EC Matrigel matrix was thawed at 4 °C overnight, and HUVECs suspended in 
DMEM were seeded in 96-well culture plates at a cell density of 50,000 cells/well after 
polymerization of the Matrigel at 37 °C for 30 min. They were then treated with 20 μL 
different concentrations of compound 16f or vehicle for 6 h at 37 °C. Then, the 
morphological changes of the cells and tubes formed were observed and photographed 
under inverted microscope (OLYMPUS, Japan). 
 
4.2.10 In vivo antitumor evaluation 
Five-week-old male Institute of Cancer Research (ICR) mice were purchased from 
Shanghai SLAC Laboratory Animals Co. Ltd. A total of 1 × 106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research, to initiate tumor growth. After incubation for one day, mice 
were weighted and at random divided into eight groups of eight animals. The groups 
treated with 16f was administered 10, 20 mg/kg in a vehicle of 10% DMF/2% Tween 
80/88% saline, respectively. The positive control group was treated with PTX (6 mg/kg) 
every 2 days by intravenous injection. CA-4 and CA-4P were administered 20 mg/kg 
in a vehicle of 10% DMF/2% Tween 80/88% saline and saline solution, respectively. 
The negative control group received a vehicle of 10% DMF/2% Tween 80/88% saline 
through intravenous injection. Treatments of 16f, CA-4 and CA-4P were done at a 
frequency of intravenous injection one dose per day for a total 21 consecutive days 
while the positive group was treated with PTX one dose per two days. The mice were 
sacrificed after the treatments and the tumors were excised and weighed. The inhibition 
rate was calculated as follows: Tumor inhibitory ratio (%) = (1-average tumor weight 
of treated group/average tumor weight of control group) × 100%. 
 
4.3 Molecular modeling  
In our study, the X-ray structure of the DMDA-colchicine-α,β-tubulin complex was 
downloaded from the Protein Data Bank (PDB code 5lyj). The protein was prepared by 
removal of the stathmin-like domain, subunits C and D, water molecules and colchicine 
using Discovery Studio modules. The docking procedure was performed by employing 
DOCK program in Discovery Studio 3.0 software, and the structural image was 
obtained using PyMOL software. 
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